A phase II study of pemetrexed plus carboplatin followed by pemetrexed maintenance therapy in chemotherapy-naive elderly patients with non-squamous non-small cell lung cancer
- Conditions
- on-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000005221
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
The 1-year survival rate was 73%(95% confidence interval(CI)56_84%).RR was 43.9%,DCR was 80.5%,median PFS was 7.23 months(95%CI 3.98_9.20), and median OS was 17.41 months(95%CI 13.60_22.83).Twenty-one patients(51.2%)were transitioned to aintenance therapy.Carboplatin and pemetrexed followed by maintenance pemetrexed for non-squamous non-small cell lung cancer in elderly patients was effective and tolerable.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 43
Not provided
1.Interstitial pneumonia or pulmonary fibrosis detectable on CT scan. 2.Patients with active co-morbidities including severe conditions. *uncontrollable angina pectoris, myocardial infarction within 3 months, severe heart disease. *uncontrollable diabetes, hypertension. *severe infection *paresis of intestine, illeus *Patients whose participation in the trial is judged to be inappropriate by the attending doctor. 3.Patients with massive pleural and cardiac effusion and ascites that need to be immediately treated. 4.Brain metastases with neurological symptoms. 5.SVC syndrome. 6.Active double cancer. 7.Pregnancy, breast feeding and suspected pregnancy. 8.History of grave drug allergic reaction. 9.Psychiatric disorder. 10.Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method